Chinese pharma tech giant Wuxi Biologics plans to spin off international business in Hong Kong IPO
Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.
Capital raised from the IPO of Wuxi XDC will go towards building new manufacturing facilities in Singapore, expanding production capacity in China, strategic investments and acquisitions, according to an exchange filing.